Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Most Oversold Penny Stocks to Buy Now. On August 18, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced receiving conditional approval for Amtagvi from Health Canada. Amtagvi is a tumor-derived T cell immunotherapy designed for adult patients with unresectable or metastatic melanoma.

Management noted that this is the first approval of Amtagvi outside the United States and marks a major milestone for the company. Moreover, the company also plans to open its first Canadian treatment center soon and expand availability to other countries with high rates of advanced melanoma.

Although the approval is conditional and is dependent on further clinical trials confirming its benefits.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) develops and delivers tumor-infiltrating lymphocyte therapies for solid tumor cancers.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.